Vapotherm, Inc. (VAPO) Stock Analysis
DELISTED 2024
What happened to Vapotherm, Inc. (VAPO) stock?
Vapotherm, Inc. (VAPO) no longer trades on public markets. It was delisted in September 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vapotherm, Inc. (VAPO) trades at $2.17. Vapotherm, Inc. focuses on developing and commercializing high velocity therapy products for respiratory distress. Their precision flow systems deliver heated, humidified, and oxygenated air to patients of all ages. Market cap: $13.6M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for VAPO: VAPO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VAPO against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
VAPO: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Vapotherm, Inc. (VAPO) Healthcare & Pipeline Overview
Vapotherm, Inc. specializes in high velocity therapy for respiratory distress, offering precision flow systems that deliver heated, humidified, and oxygenated air. Their product suite targets a range of patient ages and conditions, positioning them as a key player in the medical device industry focused on respiratory care.
What Is the Investment Thesis for VAPO?
Vapotherm, Inc. presents a focused investment opportunity within the respiratory care segment of the medical device industry. The company's proprietary high velocity therapy systems address a critical need for patients experiencing respiratory distress, offering a potential alternative to traditional methods. With a gross margin of 41.2%, there is potential for profitability as the company scales its operations. Key growth catalysts include expanding adoption of high velocity therapy in various clinical settings and geographic regions. However, the company's negative profit margin of -84.7% and a small market capitalization of $13.6M indicate substantial financial risks. Investors should carefully consider the company's ability to achieve profitability and manage its cash flow in the face of ongoing operational expenses.
Based on FMP financials and quantitative analysis
VAPO Key Highlights
Market capitalization of $13.6M indicates a small-cap company with potential for high growth but also higher risk.
- Gross margin of 41.2% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Negative profit margin of -84.7% signals significant challenges in achieving profitability.
- The company's focus on high velocity therapy positions it in a specialized segment of the respiratory care market.
- Beta of -1.10 suggests the stock price is less volatile than the overall market.
Who Are VAPO's Competitors?
VAPO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FISV Fiserv, Inc. | $51.38 | -1.33% | $27.4B | 57 |
| EW Edwards Lifesciences Corporation | $92.28 | +1.43% | $53.1B | 93 |
| MEDP Medpace Holdings, Inc. | $612.64 | +0.72% | $17.1B | 94 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VAPO's Key Strengths?
Proprietary high velocity therapy technology
- Focus on a specialized segment of the respiratory care market
- Established relationships with hospitals
- Comprehensive product portfolio
What Are VAPO's Weaknesses?
Negative profit margin
- Small market capitalization
- Limited geographic reach
- Dependence on a single product category
What Could Drive VAPO Stock Higher?
Expansion of high velocity therapy into new clinical applications.
- Increased adoption of Vapotherm systems in home healthcare settings.
- Publication of clinical data supporting the efficacy of high velocity therapy.
- Strategic partnerships to expand product portfolio and market reach.
What Are the Key Risks for VAPO?
Financial-distress signal — its Altman Z-Score of -14.22 sits in the distress zone (elevated bankruptcy risk).
- Competition from established medical device companies with greater resources.
- Technological obsolescence of Vapotherm's proprietary technology.
- Changes in healthcare regulations that could impact reimbursement rates.
- Negative profit margin and challenges in achieving profitability.
- Dependence on a single product category, making the company vulnerable to market shifts.
What Are the Growth Opportunities for VAPO?
- Expansion into New Geographic Markets: Vapotherm has the opportunity to expand its sales and marketing efforts into new geographic regions, particularly in developing countries where access to advanced respiratory care is limited. This expansion could significantly increase the company's revenue base and market share. The global market for respiratory devices is projected to grow, offering a favorable environment for international expansion. Timeline: Ongoing.
- Increased Adoption in Home Healthcare: The company can explore opportunities to adapt its high velocity therapy systems for use in the home healthcare setting. This would allow patients to receive respiratory support in the comfort of their own homes, reducing the need for hospitalizations and improving patient outcomes. The home healthcare market is experiencing rapid growth, driven by an aging population and increasing demand for cost-effective healthcare solutions. Timeline: Ongoing.
- Development of New Applications for High Velocity Therapy: Vapotherm can invest in research and development to explore new applications for its high velocity therapy technology. This could include using the technology to treat other respiratory conditions, such as asthma, COPD, and pneumonia. Expanding the applications of high velocity therapy would broaden the company's addressable market and create new revenue streams. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Vapotherm could pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Partnering with or acquiring complementary companies in the respiratory care space would allow Vapotherm to offer a more comprehensive suite of solutions to its customers and gain access to new markets. The medical device industry is characterized by consolidation, creating opportunities for strategic alliances and acquisitions. Timeline: Ongoing.
- Clinical Data and Research: Vapotherm should invest in clinical studies to demonstrate the efficacy and cost-effectiveness of its high velocity therapy systems. Publishing clinical data in peer-reviewed journals would enhance the company's credibility and support its marketing efforts. Strong clinical evidence is essential for driving adoption of new medical technologies. Timeline: Ongoing.
What Are VAPO's Competitive Advantages?
- Proprietary high velocity therapy technology.
- Established relationships with hospitals and healthcare providers.
- Strong brand reputation in the respiratory care market.
- Patents protecting its key technologies.
What Does VAPO Do?
Founded in 1993 and headquartered in Exeter, New Hampshire, Vapotherm, Inc. is a medical technology company dedicated to the development and commercialization of innovative respiratory therapy solutions. The company's core focus is on high velocity therapy, utilizing proprietary technology to treat patients of all ages suffering from respiratory distress. Vapotherm's flagship products are its precision flow systems, including the Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox. These systems deliver heated, humidified, and oxygenated air at a high velocity through a small-bore nasal interface, providing effective respiratory support. Beyond the core systems, Vapotherm offers a range of companion products designed to enhance the patient experience and streamline clinical workflows. These include the Vapotherm Transfer Unit, which facilitates patient mobility and transfers within the hospital, the Q50 compressor, which provides the necessary compressed air for the precision flow systems, and aerosol aeroneb adaptors for medication delivery. The company also provides disposable products, such as single-use disposables and nasal interfaces, as well as Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm sells directly to hospitals across the United States and internationally.
What Products and Services Does VAPO Offer?
- Develops high velocity therapy products for respiratory distress.
- Commercializes proprietary medical devices for patients of all ages.
- Offers precision flow systems that deliver heated, humidified, and oxygenated air.
- Provides companion products to enhance patient comfort and clinical workflows.
- Sells disposable products, including single-use disposables and nasal interfaces.
- Offers Oxygen Assist Modules to help clinicians maintain target oxygen levels.
How Does VAPO Make Money?
- Sells precision flow systems and related accessories to hospitals.
- Generates revenue from the sale of disposable products, such as nasal interfaces and circuits.
- Provides service and support for its installed base of equipment.
- Focuses on direct sales and marketing to hospitals and healthcare providers.
What Industry Does VAPO Operate In?
Vapotherm operates within the medical device industry, specifically in the respiratory care segment. This market is driven by factors such as an aging population, increasing prevalence of respiratory diseases, and technological advancements in respiratory therapy. The competitive landscape includes established medical device companies as well as smaller, specialized players. Vapotherm's focus on high velocity therapy differentiates it from competitors offering traditional oxygen delivery methods.
Who Are VAPO's Key Customers?
- Hospitals and acute care facilities.
- Neonatal intensive care units (NICUs).
- Pediatric intensive care units (PICUs).
- Emergency departments.
Company Profile
Vapotherm, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Exeter, US. The company is led by CEO Joseph F. Army. VAPO has traded publicly since 2018.
Vapotherm, Inc. (VAPO) Valuation Context
Valued at $13.6M, VAPO is classified as a micro-cap stock.
Key Financial Metrics
Return on equity for Vapotherm, Inc. stands at 139.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -75.0%, showing how much profit it generates from its asset base. A current ratio of 2.43 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Vapotherm, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -14.22 places it in the distress zone, a signal of elevated financial risk.
VAPO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Vapotherm's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively as discussions around innovative respiratory therapies gain traction, reflecting optimism about product demand.
- Analysts highlight Vapotherm's advancements in technology, positioning it well within the growing telehealth market, which is attracting investor interest.
- Positive press coverage regarding successful clinical trials has bolstered public perception, enhancing the company's reputation in the healthcare sector.
Bear Case
- Concerns over regulatory hurdles persist, as the healthcare industry faces increased scrutiny which could delay product approvals.
- Community discussions reveal skepticism about the company's ability to scale operations effectively, raising doubts about long-term growth prospects.
- Market sentiment has been tempered by broader economic uncertainties, leading some investors to adopt a cautious stance on healthcare stocks like Vapotherm.
- Recent earnings reports have shown mixed results, creating apprehension among investors regarding the company's financial stability moving forward.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VAPO Latest News
No recent news available for VAPO.
Leadership: Joseph F. Army
CEO
Joseph F. Army serves as the Chief Executive Officer of Vapotherm, Inc. His background includes extensive experience in the medical device industry, with a focus on commercialization and strategic leadership. Prior to joining Vapotherm, he held leadership positions at various medical technology companies, where he was responsible for driving revenue growth and expanding market share. His expertise spans across sales, marketing, and product development. He brings a wealth of knowledge in navigating the complexities of the healthcare market.
Track Record: Under Joseph F. Army's leadership, Vapotherm has focused on expanding the adoption of its high velocity therapy systems and developing new applications for its technology. Key milestones include securing regulatory approvals for new products and expanding the company's sales and marketing efforts. He has overseen the company's efforts to strengthen its relationships with hospitals and healthcare providers and to build a strong brand reputation in the respiratory care market.
VAPO Healthcare Stock FAQ
What happened to Vapotherm, Inc. (VAPO) stock?
Vapotherm, Inc. (VAPO) no longer trades on public markets. It was delisted in September 2024. The figures below are historical and are not a current quote.
Can I still buy VAPO shares?
No. VAPO stopped trading on public markets in September 2024, so the shares are not available through a broker. Anything you see quoted for VAPO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before VAPO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Vapotherm, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Vapotherm, Inc. do?
Vapotherm, Inc. is a medical technology company that develops and commercializes high velocity therapy products for patients suffering from respiratory distress. Their primary product is a precision flow system that delivers heated, humidified, and oxygenated air at a high velocity through a small-bore nasal interface.
What do analysts say about VAPO stock?
Analyst coverage of VAPO stock is limited due to its small market capitalization. However, the consensus view is that the company has potential for growth in the respiratory care market, driven by its proprietary high velocity therapy technology. Key valuation metrics, such as price-to-sales ratio, are difficult to interpret due to the company's negative profit margin.
What are the main risks for VAPO?
The main risks for Vapotherm, Inc. include competition from larger, more established medical device companies, the potential for technological obsolescence, and changes in healthcare regulations that could impact reimbursement rates. The company's negative profit margin and small market capitalization also pose significant financial risks.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Market projections are based on industry reports and analyst estimates.
- Competitive landscape is subject to change.